Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 8:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Niravam Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

PharmacofMRI (Functional Magnetic Resonance Imaging) of Anxiolytic Medications (Alprazolam)

NCT00703885
View directory record Official record
Conditions
Anxiety Disorders
Interventions
0.25 mg alprazolam, 1.0 mg alprazolam, placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 30 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Dec 21, 2014 · Synced Sep 24, 2026, 8:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Alprazolam Extended-Release 3mg Tablets Bioequivalence Study Under Non-fasting Conditions

NCT00830024
View directory record Official record
Conditions
Healthy
Interventions
Alprazolam Extended-Release 3 mg Tablets
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
2
States / cities
East Grand Forks, Minnesota • Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Sep 24, 2026, 8:20 AM EDT
Completed Phase 4 Interventional Results available

Trial to Compare Time to Response in the Symptoms of Anxiety to Concomitant Treatment With Niravam™ and an SSRI or SNRI to Treatment With an SSRI or SNRI Alone in Subjects With Generalized Anxiety Disorder or Panic Disorder

NCT00266409
View directory record Official record
Conditions
Generalized Anxiety Disorder, Panic Disorder
Interventions
Niravam, SSRI/SNRI
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 26, 2014 · Synced Sep 24, 2026, 8:20 AM EDT
Completed Phase 2 Interventional Results available

Staccato Alprazolam in Panic Attack

NCT00477451
View directory record Official record
Conditions
Treatment of Induced Panic Attack
Interventions
Inhaled placebo, Inhaled alprazolam 1 mg, Inhaled alprazolam 2 mg, IV doxapram
Drug
Lead sponsor
Alexza Pharmaceuticals, Inc.
Other
Eligibility
18 Years to 55 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
3
States / cities
Brooklyn, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 15, 2017 · Synced Sep 24, 2026, 8:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Relative Bioavailability Study of Staccato Alprazolam Versus Oral Alprazolam in Healthy Study Participants

NCT05626439
View directory record Official record
Conditions
Healthy Participants
Interventions
Staccato alprazolam, Oral alprazolam
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years to 55 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 17, 2024 · Synced Sep 24, 2026, 8:20 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Gabapentin Treatment of Benzodiazepine Dependence

NCT01893632
View directory record Official record
Conditions
Benzodiazepine Dependence
Interventions
gabapentin, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Sep 24, 2026, 8:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of the Abuse Potential of Lasmiditan in Participants Who Are Recreational Drug Users

NCT03286218
View directory record Official record
Conditions
Recreational Drug Use, Prescription Drug Abuse (Not Dependent)
Interventions
Lasmiditan, Alprazolam, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 9, 2020 · Synced Sep 24, 2026, 8:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Relative Bioavailability Study of Alprazolam 3 mg Extended Release Tablets Under Non-fasting Conditions

NCT00865657
View directory record Official record
Conditions
Healthy
Interventions
Alprazolam 3 mg Extended Release Tablets, single dose, XANAX XR® 3 mg tablets, single dose
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 16, 2010 · Synced Sep 24, 2026, 8:20 AM EDT
Recruiting Phase 1Phase 2 Interventional

Opioid Drug Interaction Study

NCT06757140
View directory record Official record
Conditions
Drug Interactions, Drug Kinetics
Interventions
Alprazolam, Oxycodone, Placebo
Drug
Lead sponsor
Shanna Babalonis, PhD
Other
Eligibility
18 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Sep 24, 2026, 8:20 AM EDT
Completed Phase 2 Interventional Results available

Staccato Alprazolam and Photoparoxysmal Response

NCT02351115
View directory record Official record
Conditions
Epilepsy
Interventions
A=Placebo, B=Inhaled Alprazolam 0.5 mg, C=Inhaled Alprazolam 1 m, D= Inhaled Alprazolam 2 mg, E=Placebo
Drug
Lead sponsor
Nova Pneuma Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Boise, Idaho • New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Sep 24, 2026, 8:20 AM EDT
Enrolling by invitation Phase 3 Interventional

A Study to Test the Safety and Tolerability of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures

NCT05076617
View directory record Official record
Conditions
Stereotypical Prolonged Seizures
Interventions
Staccato alprazolam
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
12 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
48
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 36 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 24, 2026, 8:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fed Study of Alprazolam Extended-release Tablets 3 mg to Xanax XR® Tablets 3 mg

NCT00650299
View directory record Official record
Conditions
Healthy
Interventions
Alprazolam Extended-release Tablets 3 mg, Xanax XR® Tablets 3 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Sep 24, 2026, 8:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics Of Alprazolam Sublingual Tablet Versus Conventional Tablet

NCT01256151
View directory record Official record
Conditions
Anxiety Disorder
Interventions
Alprazolam tablet, Alprazolam sublingual
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 27, 2021 · Synced Sep 24, 2026, 8:20 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Mechanisms of Hypoglycemia Associated Autonomic Dysfunction Question 2

NCT00574639
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Alprazolam, Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 50 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 11, 2019 · Synced Sep 24, 2026, 8:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Hallucinogens and Other Drugs on Mood and Performance

NCT02033707
View directory record Official record
Conditions
Healthy
Interventions
Hallucinogens and psychoactive substances
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 15, 2019 · Synced Sep 24, 2026, 8:20 AM EDT
Terminated Phase 4 Interventional

A Study To Assess the Safety of Extended Release Alprazolam for the Treatment of Adolescents With Panic Disorder or Anxiety With Panic Attacks

NCT00634790
View directory record Official record
Conditions
Panic Disorder
Interventions
alprazolam XR
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
13 Years to 17 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
47
States / cities
Little Rock, Alaska • Phoenix, Arizona • Scottsdale, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2021 · Synced Sep 24, 2026, 8:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Licorice Botanical Dietary Supplements - Metabolism and Safety in Women

NCT03948243
View directory record Official record
Conditions
Food-drug Interaction
Interventions
Licorice, Alprazolam 2 MG, Caffeine 100 MG, Tolbutamide 250 mg, Dextromethorphan 30mg
Dietary Supplement · Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
40 Years to 79 Years · Female only
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 5, 2023 · Synced Sep 24, 2026, 8:20 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Opiates and Benzodiazepines on Driving

NCT03447353
View directory record Official record
Conditions
Driving Behavior
Interventions
Xanax 1Mg Tablet, Norco 10Mg-325Mg Tablet, Placebo Oral Tablet
Drug
Lead sponsor
Timothy L. Brown
Other
Eligibility
18 Years to 40 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Sep 26, 2018 · Synced Sep 24, 2026, 8:20 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Evaluation Of PF-00572778 And Alprazolam On Naloxone Challenge In Healthy Subjects

NCT00580190
View directory record Official record
Conditions
Healthy
Interventions
alprazolam, Placebo, PF-00572778
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 13, 2009 · Synced Sep 24, 2026, 8:20 AM EDT
Completed Phase 2Phase 3 Interventional Results available

D-cycloserine and Virtual Reality Exposure to Treat Iraq War Veterans With PTSD

NCT00356278
View directory record Official record
Conditions
Stress Disorder, Post Traumatic
Interventions
D-Cycloserine, Alprazolam, Virtual Reality Exposure Therapy, Placebo
Drug · Behavioral
Lead sponsor
Emory University
Other
Eligibility
21 Years to 65 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 7, 2016 · Synced Sep 24, 2026, 8:20 AM EDT
Terminated Phase 4 Interventional

A Study to Assess the Long-term Use of Alprazolam Extended Release (XL) in the Treatment of Adolescents With Panic Disorder

NCT00635076
View directory record Official record
Conditions
Panic Disorder
Interventions
placebo, alprazolam XR
Other · Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
13 Years to 17 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
3
States / cities
Eugene, Oregon • San Antonio, Texas • Middleton, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 27, 2021 · Synced Sep 24, 2026, 8:20 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

An Abuse Potential Study of Orally Administered HORIZANT in Healthy, Non-dependent, Recreational Drug Users

NCT06097676
View directory record Official record
Conditions
Abuse Potential
Interventions
Placebo, Alprazolam 2 mg, Gabapentin Enacarbil Immediate Release (GE-IR) 200 mg, Gabapentin Enacarbil Immediate Release (GE-IR) 450 mg, Gabapentin Enacarbil Immediate Release (GE-IR) 700 mg
Drug
Lead sponsor
Arbor Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 11, 2024 · Synced Sep 24, 2026, 8:20 AM EDT
Completed Phase 2 Interventional

Phase II Double-Blind, Placebo-Controlled Study of the Reinforcing Effects of Alprazolam in Patients With Anxiety

NCT00004373
View directory record Official record
Conditions
Anxiety Disorder, Panic Disorder
Interventions
alprazolam
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 50 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2001
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 24, 2026, 8:20 AM EDT
Recruiting Phase 3 Interventional

A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures

NCT05077904
View directory record Official record
Conditions
Stereotypical Prolonged Seizures
Interventions
Staccato alprazolam, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
12 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
66
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 50 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 24, 2026, 8:20 AM EDT